| Synonym |
| Thai / English name |
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : curcuminType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : curcumin 60 mg/kgDuration : 4 weeksType of interaction : PharmacodynamicsInteraction with drug : InsulinDose/Conc.(drug) : -Result : PositiveRemark :Note : Result: Chronic treatment with insulin (10 IU/kg/day, s.c.) and its combinations with curcumin (60 mg/kg, p.o.) for 4 weeks starting from the 4th week of STZ injection significantly attenuated thermal hyperalgesia and the hot-plate latencies. There was a significant inhibition of TNF-alpha and NO levels when these drugs were given in combination compared with their effects per se.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : CurcuminType of experiment : -Type of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Curcumin inhibits P-gp, but has very poor oral bioavailability. Caution in patients taking high doses with anticoagulants or antiplatelet drugs.Note : Data incomplete, data from review article.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : curcuminType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : InsulinDose/Conc.(drug) : -Result : PositiveRemark : Type of study = C2C12 (mouse myoblast cell line)Note : There can be a synergistic interaction between curcumin and insulin in glucose metabolism-associated cell signaling, such as AMPK/ACC, Pl3-kinase/Akt and GLUT4 pathways.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 100 microgram/mlDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : IC50=17.0 microgram/ml
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 100 microgram/mlDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : IC50=14.8 microgram/ml
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : CurcuminType of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 100 mg/kgDuration : 7 daysType of interaction : PharmacokineticsInteraction with drug : LosartanDose/Conc.(drug) : 10 mg/kgResult : PositiveRemark : - Rats were gavaged with losartan 10 mg/kg after repeat oral dose of curcumin 100 mg/kg for 7 days. Result: Rats prior exposure to curcumin had significantly increased in AUC0-t and Cmax of the oral losartan. Administration of 10 mg/kg losartan in the treatment group resulted in a marked increase in the AUC0-t and Cmax from 2080+/-837 to 3460+/-1350 micrograms/L. h and 475+/-63.1 to 1660+/-892 micrograms/L, respectively. An approximate 1.7-fold increace of the AUC0-t and 3.5-fold increase of the Cmax in treatment group.
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : CurcuminType of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 100 mg/kgDuration : 7 daysType of interaction : PharmacokineticsInteraction with drug : LosartanDose/Conc.(drug) : 10 mg/kgResult : PositiveRemark : - Rats were gavaged with losartan 10 mg/kg after repeat oral dose of curcumin 100 mg/kg for 7 days. Result: The AUC0-t and Cmax of losartan metabolite EXP3174 of treatment group were significantly increased from 766+/-416 to 1460+/-818 micrograms/L. h and 108+/-61.1 to 341+/-187 micrograms/L, respectively. Tmax of EXP3174 of the control group was nonsignificantly 78% higher than that of group pre-treated with curcumin (3.33+/-2.34 to 1.88+/-0.64 h).
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : Aqueous, ethanolType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 2 -32 mg/lDuration : -Type of interaction : PharmacokineticsInteraction with drug : FluconazoleDose/Conc.(drug) : 0.5 - 128 mg/lResult : -Remark : This study suggests that curcumin is not only a natural compound capable of inhibiting Candida albicans growth, but is also able to act synergistically with fluconazole as an MFS inhibitor in low doses.Note : MFS = major facilitator superfamily
Part Used : -Activity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Sirolimus*/RapamycinDose/Conc.(drug) : -Result : PositiveRemark : When curcumin was combined at concentrations of 1.25-2.5 micromolar with sirolimus at concentrations from 0.63 to 1.25 mg/ml the effects were synergistic. Combination of curcumin (1.25-2.5 micromolar) with sirolimus (5 nanogram/ml) showed additive effects.
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : Oxacillin*/Oxazocillin/Methylphenylisoxazolyl (MPI) penicillin/Oxacilline/OxacillinumDose/Conc.(drug) : -Result : PositiveRemark : The time kill curves showed that a combined curcumin and oxacillin treatment reduced the bacterial counts below the lowest detectable limit after 24 h. This study suggested that curcumin reduced the minimal inhibitory concentration (MIC) of several antibiotics tested, notably of oxacillin, ampicillin, ciprofloxacin and norfloxacin, and that curcumin in combination with antibiotics could lead to the development of new combination of antibiotics against Methicillin-resistant Stapphylococcus aureus (MRSA) infection.
